> Details

Vlachogiannis, Georgios; Hedayat, Somaieh; Vatsiou, Alexandra; Jamin, Yann; Fernández-Mateos, Javier; Khan, Khurum; Lampis, Andrea; Eason, Katherine; Huntingford, Ian; Burke, Rosemary; Rata, Mihaela; Koh, Dow-Mu; Tunariu, Nina; Collins, David; Hulkki-Wilson, Sanna; Ragulan, Chanthirika; Spiteri, Inmaculada; Moorcraft, Sing Yu; Chau, Ian; Rao, Sheela; Watkins, David; Fotiadis, Nicos; Bali, Maria; Darvish-Damavandi, Mahnaz; [...]

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
  • Contributor: Vlachogiannis, Georgios; Hedayat, Somaieh; Vatsiou, Alexandra; Jamin, Yann; Fernández-Mateos, Javier; Khan, Khurum; Lampis, Andrea; Eason, Katherine; Huntingford, Ian; Burke, Rosemary; Rata, Mihaela; Koh, Dow-Mu; Tunariu, Nina; Collins, David; Hulkki-Wilson, Sanna; Ragulan, Chanthirika; Spiteri, Inmaculada; Moorcraft, Sing Yu; Chau, Ian; Rao, Sheela; Watkins, David; Fotiadis, Nicos; Bali, Maria; Darvish-Damavandi, Mahnaz; [...]
  • Published: American Association for the Advancement of Science (AAAS), 2018
  • Published in: Science, 359 (2018) 6378, Seite 920-926
  • Language: English
  • DOI: 10.1126/science.aao2774
  • ISSN: 0036-8075; 1095-9203
  • Origination:
  • Footnote:
  • Description: <jats:title>Cancer organoids to model therapy response</jats:title> <jats:p> Cancer organoids are miniature, three-dimensional cell culture models that can be made from primary patient tumors and studied in the laboratory. Vlachogiannis <jats:italic>et al.</jats:italic> asked whether such “tumor-in-a-dish” approaches can be used to predict drug responses in the clinic. They generated a live organoid biobank from patients with metastatic gastrointestinal cancer who had previously been enrolled in phase I or II clinical trials. This allowed the authors to compare organoid drug responses with how the patient actually responded in the clinic. Encouragingly, the organoids had similar molecular profiles to those of the patient tumor, reinforcing their value as a platform for drug screening and development. </jats:p> <jats:p> <jats:italic>Science</jats:italic> , this issue p. <jats:related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" issue="6378" page="920" related-article-type="in-this-issue" vol="359" xlink:href="10.1126/science.aao2774">920</jats:related-article> </jats:p>